Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC5876 | Xenin 8 |
| C-Terminal fragment of xenin, a neurotensin-like peptide; modulates pancreatic insulin and glucagon secretion/effects. Stimulates basal and arginine-induced insulin secretion and potentiates the insulin response to glucose (EC50 = 0.16 nM). Also potentiates arginine- and carbachol-induced glucagon secretion in a somatostatin-independent manner. | |
| BCC5877 | [Ala11,D-Leu15]-Orexin B |
| Highly potent and selective OX2 receptor agonist; displays 400-fold selectivity over OX1 receptors. EC50 values are 0.13 and 52 nM for human OX2 and OX1 receptors respectively. | |
| BCC5880 | MRS 2279 |
| Selective, high affinity competitive antagonist of the P2Y1 receptor (Ki = 2.5 nM; IC50 = 51.6 nM). Fails to block nucleotide signaling at most other P2Y receptors (P2Y2, P2Y4, P2Y6, P2Y11 and P2Y12) and potently inhibits ADP-induced aggregation of human blood platelets in vitro (pKB = 8.05). | |
| BCC5882 | BVD 10 |
| Highly selective NPY Y1 receptor antagonist. Ki values are 25.7, 1420, 2403 and 7100 nM at Y1, Y2, Y4 and Y5 receptors respectively. Devoid of agonist activity at Y4 receptors. | |
| BCC5883 | PDZ1 Domain inhibitor peptide |
| Novel cyclic peptide that disrupts interaction between GluK2 (formerlyy GluR6) and the postsynaptic density protein 95 (PSD-95). Competes with the C-terminus of GluK2 for binding to the PDZ1 domain of PSD-95. Inhibits clustering of kainate receptors. | |
| BCC5884 | Urotensin II-related peptide |
| Potent endogenous agonist for the urotensin-II (UT) receptor. Binds with high affinity and potently activates recombinant rat and human UT receptors (EC50 values are 0.55 and 4.8 nM respectively). Produces hypotensive effects following systemic administration in rats. | |
| BCC5885 | des-His1-[Glu9]-Glucagon (1-29) amide |
| Glucagon receptor antagonist (pA2 = 7.2 for inhibition of glucagon-induced adenylyl cyclase activation in rat liver membranes); displays no agonist activity. Enhances glucose-stimulated pancreatic insulin release in vitro. Blocks added glucagon-induced hyperglycemia in normal rabbits without affecting glycogenolysis in vivo. Also blocks endogenous glucagon-induced hyperglycemia in streptozocin diabetic rats. | |
| BCC5886 | Rac1 Inhibitor W56 |
| Peptide comprising residues 45-60 of the guanine nucleotide exchange factor (GEF) recognition/activation site of Rac1; selectively inhibits Rac1 interaction with Rac1-specific GEFs TrioN, GEF-H1 and Tiam1. Control peptide available. | |
